AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
Aardvark Therapeutics' shares lost more than 70% of their IPO value across two market events after the Company disclosed a Phase 3 safety pause and then a full FDA clinical hold on ARD-101, which a securities class action alleges corrected earlier representations that the drug was "99%...
Covered in this story
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.